21 March 2024 in JACC: Advances
Atrial fibrillation (AF) is the most common arrhythmia reported worldwide. There is significant heterogeneity in AF care pathways for a patient seen in the emergency room, impacting access to guideline-driven therapies. The purpose of this study was to compare the difference in AF outcomes between those treated with an organized treatment pathway vs routine-care approach. The emergency room to electrophysiology service study (ER2EP) is a multicenter, prospective observational registry (NCT04476524) enrolling patients with AF from sites where a pathway for management of AF was put in place compared to sites where a pathway was not in place within the same health system and the same physicians providing services at all sites. Multivariable regression modeling was performed to identify predictors of clinical outcomes. Beta coefficient or odds ratio was reported as appropriate. A total of 500 patients (ER2EP group, n = 250; control group, n = 250) were included in the study. The mean age was 73.4 ± 12.9 years, and 52.2% were males. There was a statistically significant difference in primary endpoint [time to ablation (56 ± 50.9 days vs 183.3 ± 109.5 days; P < 0.001), time to anticoagulation initiation (2.1 ± 1.6 days vs 19.7 ± 35 days, P < 0.001), antiarrhythmic drug initiation (4.8 ± 7.1 days vs 24.7 ± 44.4 days, P < 0.001) compared to the control group, respectively. As such, this resulted in reduced length of stay in the ER2EP group compared to the control group (2.4 ± 1.4 days vs 3.23 ± 2.5 days, P = 0.002). This study provides evidence that having an organized pathway from the emergency department for AF patients involving electrophysiology services can improve early access to definitive therapies and clinical outcomes.
28 August 2025 in JACC: Advances
Remote monitoring (RM) is the standard of care for patients with cardiac implantable electronic devices (CIEDs). Data deluge from RM of CIEDs is one of the major challenges being faced by cardiac device clinics. The purpose of this study was to highlight the role of artificial intelligence (AI) in reducing data deluge from CIEDs and to elucidate its performance in augmenting the traditional device clinic workforce. Deidentified data from RM of CIEDs from 78 device clinics across the United States were included. Transmissions processed by AI and device technicians (DTs) were compared. Around 15% of all transmissions processed were examined at random by 2 cardiac electrophysiologists who were blinded to the source of the interpretation. Over 8 months, 690,673 transmissions were generated from RM of 74,217 devices. AI processed 28.3% of the transmissions, whereas DT processed 71.7% (n = 495,054). AI forwarded 22.8% (n = 44,550) while DT forwarded 38.5% (n = 190,492) of the total processed transmissions to the device clinics. As such, only 34% (n = 235,042) of the total transmissions were forwarded to the device clinics. Considering electrophysiologist interpretation/adjudication as the gold standard, AI was 93.8% accurate with 99.1% sensitivity, 93% specificity, and an F1 score of 81%. This study presents a real-world analysis of incorporating AI in device clinic workflow to assist in interpretation and classification of RM data. AI interpretation of transmissions was found to have an accuracy similar to that of DT with superior sensitivity but lesser specificity.
21 August 2024 in Journal of Cardiovascular Electrophysiology
NPNaga Venkata K. Pothineni
Naga Venkata K. Pothineni
+6
15 June 2026 in Clinical Cardiology
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
1 December 2023 in Annals of Internal Medicine: Clinical Cases